drug pricing

Pharma Rachel Cohrs Zhang

STAT Plus: Medicare announces drug prices for historic first round of negotiations

Pharmalot Ed Silverman

STAT Plus: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B

The Readout LOUD Allison DeAngelis and Elaine Chen

VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision

Politics Rachel Cohrs Zhang, Theresa Gaffney, Lev Facher, Isabella Cueto, Sarah Owermohle, and John Wilkerson

STAT Plus: Trump’s real health care agenda isn’t in Project 2025 — it’s in his own words

Biotech Andrew Joseph

STAT Plus: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England

First Opinion Fred D. Ledley

Give pharmaceutical execs the benefit of doubt — but they need to work for it

First Opinion Melissa Barber, Joseph S. Ross, and Reshma Ramachandran

STAT Plus: To get a fair deal on Wegovy, buying Novo Nordisk might not be Medicare’s worst option

Pharmalot Bob Herman and Ed Silverman

STAT Plus: Express Scripts overcharged postal workers by $45 million, audit says

Politics Sarah Owermohle and Rachel Cohrs Zhang

STAT Plus: Harris health care agenda swiftly hailed by progressives and reproductive rights groups

Letters to the editor Patrick Skerrett

Readers respond to essays on philanthropy and nursing schools, opioid overdoses, and more

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Here come Medicare’s first negotiated drug prices

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

First Opinion Peter Rheinstein

Medicare drug pricing rules will delay access to promising therapies

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

Pharmalot Ed Silverman

STAT Plus: FTC report finds PBMs profit at the expense of patients and independent pharmacies

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

Politics Rachel Cohrs Zhang and Sarah Owermohle

STAT Plus: Biden and Trump spar over Medicare and abortion in a presidential debate filled with mistakes and falsehoods

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Key health care topics to watch out for at the Biden-Trump debate

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

The Readout Elaine Chen

STAT Plus: Intellia says its CRISPR-based therapy can be redosed

The Readout Elaine Chen

STAT Plus: One firm, two conflicting takes on Alnylam’s HELIOS-B 

The Readout Meghana Keshavan

STAT Plus: The findings from Alnylam’s highly anticipated readout  

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more

The Readout Meghana Keshavan

STAT Plus: Can JAK inhibitors bolster checkpoint inhibitors?